Veradermics Doses First Patient in Phase 2 Clinical Trial for VDMN for the Treatment of Common Warts
VDMN is an immunotherapy-containing dissolvable microarray being developed as an "injection-free" treatment for common warts
WEST HARTFORD, CONN. (PRNewswire) February 27, 2023
Veradermics Inc., a clinical-stage medical dermatology company with a pipeline of first-in-class product candidates targeting highly prevalent skin conditions, today announced that it has commenced enrollment in a Phase 2, 150-subject, randomized, double-blind, placebo-controlled clinical trial assessing the safety and efficacy of VDMN in Verruca Vulgaris (common warts).
VDMN is an investigational, proprietary, dissolvable microarray patch technology which administers immunotherapy within the superficial aspect of the skin. It is anticipated that this first-in-category technology will provide an “injection-free” immunotherapy treatment for common warts without creating the degree of pain, “needle-phobia,” and anxiety associated with traditional injections. VDMN has the potential to become a preferred treatment approach for children and young adults where aversion to painful procedures involving needles or freezing with liquid nitrogen and common wart prevalence are all at their highest.
“Common warts, which impact approximately 19 million people in the U.S. alone, are one of the most frequent reasons that Americans seek treatment for skin disease,” said Reid Waldman, M.D., CEO at Veradermics. “Despite their high prevalence, there are no FDA approved prescription treatments for common warts. VDMN has the potential to satisfy patient and dermatologist hopes for a convenient, patient-friendly, and effective treatment. The start of our Phase 2 program for VDMN in common warts is a pivotal milestone for Veradermics as the company advances the first product of its pipeline candidates into the clinic.”
VDMN is intended to locally stimulate the immune system resulting in immune system recognition and clearance of the virus that causes common warts – the human papillomavirus (HPV). VDMN is applied immediately adjacent to the wart and left in place for five minutes prior to removal. During this time, the dissolvable microarray releases the immunotherapy-based active ingredient into the epidermis and superficial dermis. In this dose-ranging Phase 2 study, qualified subjects will receive therapy every three weeks for up to six treatments.
"We are very excited to announce the first patient dosed with VDMN, our flagship product candidate,” said Tim Durso, MD, President at Veradermics. “Treatments for common warts are a critical unmet need in dermatology for which there has been limited advancements for decades. We are optimistic about the potential for VDMN to bring much-needed change to the common wart treatment landscape and look forward to conducting this study.”
About Common Warts
Common warts are a viral skin infection caused by HPV. Common warts affect ~19 million Americans and result in approximately 2.2 million visits with a healthcare provider annually in the U.S. alone. Common warts may persist for years without treatment. Currently, there are no FDA approved prescription treatments for this condition.
About VeraDermics Inc.
VeraDermics Inc. is a dermatology-focused pharmaceutical company with a pipeline of patient-friendly therapeutics aimed at helping individuals affected by skin diseases. VeraDermics portfolio includes therapeutics addressing common warts, genital warts, alopecia areata, molluscum contagiosum, and beyond .
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "believe", "may" and "will" and similar expressions, are intended to identify forward-looking statements. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of Veradermic’s management about VDMN as treatment for patients with skin disease. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements. The forward-looking statements are made as of this date and Veradermics does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Chief Executive Officer
SOURCE Veradermics Inc.